Showing results (301-310 of 446) with videos related to
Sort By:
Pageof 45
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.Nature Communications|June 11, 2026
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanomaAndrea Di Pietro, Lewis Au, Patrick Crock, et al.The Lancet. Oncology|October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialRobert J Motzer, Thomas E Hutson, Hilary Glen, et al.The Journal of Pathology|February 25, 2012
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic targetMarco Gerlinger, Claudio R Santos, Bradley Spencer-Dene, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.Journal of Translational Medicine|June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyLuis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.European Urology|May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled AnalysisMaxine Sun, Lorenzo Marconi, Tim Eisen, et al.European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.Pageof 45